IDRx
Executives
View the org chart displaying its 13 main executives
Most searched biographies at IDRx
Popular executive movements at IDRx
- David Kerstein has joined the company as Chief Medical Officer (posted on March 27 2024).
- Brad Dahms has joined the company as Chief Financial Officer and Chief Business Officer (posted on March 12 2024).
- Tim Clackson has joined the company as Chief Executive Officer (posted on March 12 2024).
Create your alert
to follow the executive moves at IDRx.
Biotechnology
IDRx has 2,289 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Delphia Therapeutics has just announced a $67 Million fundraising (posted on May 7 2024).
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by IDRx
- IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer | IDRx
- IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO | IDRx
- IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST | IDRx
- IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapies | IDRx
Social media about IDRx
- IDRx on Wikipedia, Google News & Yahoo Finance
- IDRx on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Eli Casdin 
